-
3 weeks ago | 
labiotech.eu | Willow Shah-Neville
Take a look at 12 of the top AI drug discovery companies around today, using their technology to speed up the drug discovery process.
-
Jan 13, 2025 | 
labiotech.eu | Willow Shah-Neville
From AI to gene therapy, we reached out to industry experts to get their thoughts on the trends that will shape the biotech industry in 2025.
-
Dec 16, 2024 | 
labiotech.eu | Willow Shah-Neville
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*CommentsThis field is for validation purposes and should be left unchanged. Last year, we documented nine biotechs we thought you should watch in 2024.
-
Dec 11, 2024 | 
labiotech.eu | Willow Shah-Neville
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged.
-
Dec 9, 2024 | 
labiotech.eu | Willow Shah-Neville
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. When German scientists posted data in 2022 showing that CAR-T cell therapy could be effective in treating systemic lupus erythematosus, interest in the field quickly took off.
-
Dec 5, 2024 | 
labiotech.eu | Willow Shah-Neville
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. The companies Metsera, Alentis Therapeutics, and Adcendo bagged the biggest private biotech investments in November 2024.
-
Dec 4, 2024 | 
labiotech.eu | Willow Shah-Neville
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. As big pharma faces a looming patent cliff that could put more than $200 billion in annual revenue at risk through 2030, it opens up a major opportunity for biosimilar developers.
-
Nov 28, 2024 | 
labiotech.eu | Willow Shah-Neville
Antisense oligonucleotides are essentially short, single-stranded synthetic fragments of DNA or RNA that bind specifically to the target RNA sequence inside cells and modulate protein expression through several different mechanisms, blocking the ability of the RNA to make a protein or function in other ways. In recent years, these drugs have gained popularity among drug developers, as they are a highly specific, targeted treatment that can treat a wide range of diseases.
-
Nov 22, 2024 | 
labiotech.eu | Willow Shah-Neville
Building on the foundations of its hugely successful AlphaFold2, which made a fundamental breakthrough in protein structure prediction in 2020, Google DeepMind and its sister company Isomorphic Labs launched AlphaFold3 in May.
-
Nov 19, 2024 | 
labiotech.eu | Willow Shah-Neville
Bispecific antibodies seem to be all the rage at the minute. Their ability to deliver targeted therapeutics to patients with a two-in-one approach by simultaneously binding to two different antigens or epitopes makes them an extremely attractive proposition to drug developers. This can be seen in the fact that there have been multiple big buyouts over the last few months by big pharma and big biotechs of bispecific antibody companies or assets.
